Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ingen Technologies, Inc. (IGNT)
Riverside, CA, US
Ingen Technologies, Inc. engages in the manufacture of respiratory medical devices. Its products include oxygen flow meters and nasal cannulas that trade under the trademark name of Oxyview and Smart Nasal Cannula. The company was founded in 1999 and is headquartered in Riverside, CA.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -9.09% | +0.00% | +0.00% | +0.00% | +100.00% | +100.00% | -97.50% | -80.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%-99.8% Q4'08: -95.3% (vs Q2'07)
-
EPS growth Medical - Instruments & Supplies: +16.3%+80.0% ★
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+17,198.7% Q4'08: -1,284.6% (vs Q2'07)
-
EBIT margin Medical - Instruments & Supplies: +13.5%-4,821.2% Q4'08: -10,022.8% (vs Q2'07)
-
ROIC Medical - Instruments & Supplies: +6.0%— Q4'08: +28.4% (vs Q2'07)
-
Share dilution Medical - Instruments & Supplies: +0.1%-99.7% ★
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×— Q4'08: -1.08× (vs Q2'07)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gary Tilden | Chairman of the Board, Chief Operating Officer & Secretary | 120.0K | male |
| David S. Hanson | Chief Executive Officer & Director | — | male |
| Richard O. Weed | General Counsel | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IGNT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
